Suppliers / Hubei Haosun Pharmaceutical

Hubei Haosun Pharmaceutical

China 3 duplicate records merged Updated 9 July 2026

Hubei Haosun Pharmaceutical is an API manufacturer based in China. It holds 6 valid CEPs across a filed portfolio of 5 molecules. Its GMP standing is certified by EMA.

0
active US DMFs
6
valid CEPs
1
registered plants
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
EU GMP
1 of 1 confirmed
Sources: EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Registered plants

Site FDA FEI
Ezhou, China Not on file

What they file, and where

Molecule Regulators Docs
Amisulpride EDQM, SFDA (Saudi Arabia) 2
Docetaxel EDQM 2
Flumazenil EDQM, SFDA (Saudi Arabia) 2
Granisetron EDQM 1
Irinotecan EDQM 1

Also appears on these molecule pages

Amisulpride API Docetaxel API Flumazenil API Granisetron API Irinotecan API

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Hubei Haosun Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates